Literature DB >> 31229387

One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose.

Scott G Weiner1, Olesya Baker2, Dana Bernson3, Jeremiah D Schuur4.   

Abstract

STUDY
OBJECTIVE: Despite the increased availability of naloxone, death rates from opioid overdose continue to increase. The goal of this study is to determine the 1-year mortality of patients who were treated for a nonfatal opioid overdose in Massachusetts emergency departments (EDs).
METHODS: This was a retrospective observational study of patients from 3 linked statewide Massachusetts data sets: a master demographics list, an acute care hospital case-mix database, and death records. Patients discharged from the ED with a final diagnosis of opioid overdose were included. The primary outcome measure was death from any cause within 1 year of overdose treatment.
RESULTS: During the study period, 17,241 patients were treated for opioid overdose. Of the 11,557 patients who met study criteria, 635 (5.5%) died within 1 year, 130 (1.1%) died within 1 month, and 29 (0.25%) died within 2 days. Of the 635 deaths at 1 year, 130 (20.5%) occurred within 1 month and 29 (4.6%) occurred within 2 days.
CONCLUSION: The short-term and 1-year mortality of patients treated in the ED for nonfatal opioid overdose is high. The first month, and particularly the first 2 days after overdose, is the highest-risk period. Patients who survive opioid overdose should be considered high risk and receive interventions such as being offered buprenorphine, counseling, and referral to treatment before ED discharge.
Copyright © 2019 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31229387      PMCID: PMC6920606          DOI: 10.1016/j.annemergmed.2019.04.020

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  3 in total

1.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

2.  Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016.

Authors:  Puja Seth; Lawrence Scholl; Rose A Rudd; Sarah Bacon
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-03-30       Impact factor: 17.586

3.  Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses - United States, July 2016-September 2017.

Authors:  Alana M Vivolo-Kantor; Puja Seth; R Matthew Gladden; Christine L Mattson; Grant T Baldwin; Aaron Kite-Powell; Michael A Coletta
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-03-09       Impact factor: 17.586

  3 in total
  43 in total

1.  Ambulance Calls for Substance-Related Issues Before and After COVID-19.

Authors:  Scott G Weiner; Rebecca E Cash; Michelle Hendricks; Sanae El Ibrahimi; Olesya Baker; Raghu R Seethala; Gregory Peters; Scott A Goldberg
Journal:  Prehosp Emerg Care       Date:  2020-12-15       Impact factor: 3.077

2.  Mortality Following Nonfatal Opioid and Sedative/Hypnotic Drug Overdose.

Authors:  Sidra Goldman-Mellor; Mark Olfson; Cristina Lidon-Moyano; Michael Schoenbaum
Journal:  Am J Prev Med       Date:  2020-05-07       Impact factor: 5.043

3.  Missed Opportunities to Save Lives-Treatments for Opioid Use Disorder After Overdose.

Authors:  Elizabeth M Schoenfeld; Lauren M Westafer; William E Soares
Journal:  JAMA Netw Open       Date:  2020-05-01

4.  Risk and protective factors for repeated overdose after opioid overdose survival.

Authors:  Brian Suffoletto; Amy Zeigler
Journal:  Drug Alcohol Depend       Date:  2020-02-05       Impact factor: 4.492

Review 5.  Countermeasures for Preventing and Treating Opioid Overdose.

Authors:  Charles P France; Gerard P Ahern; Saadyah Averick; Alex Disney; Heather A Enright; Babak Esmaeli-Azad; Arianna Federico; Lisa R Gerak; Stephen M Husbands; Benedict Kolber; Edmond Y Lau; Victoria Lao; David R Maguire; Michael A Malfatti; Girardo Martinez; Brian P Mayer; Marco Pravetoni; Niaz Sahibzada; Phil Skolnick; Evan Y Snyder; Nestor Tomycz; Carlos A Valdez; Jim Zapf
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.875

6.  Increasing Naloxone Prescribing in the Emergency Department Through Education and Electronic Medical Record Work-Aids.

Authors:  Mary Funke; Marcus C Kaplan; Holly Glover; Nicole Schramm-Sapyta; Andrew Muzyk; Jennifer Mando-Vandrick; Alexander Gordee; Maragatha Kuchibhatla; Emily Sterrett; Stephanie A Eucker
Journal:  Jt Comm J Qual Patient Saf       Date:  2021-03-06

7.  A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs.

Authors:  Kathryn Hawk; Lauretta E Grau; David A Fiellin; Marek Chawarski; Patrick G O'Connor; Nikolas Cirillo; Chris Breen; Gail D'Onofrio
Journal:  Acad Emerg Med       Date:  2021-02-28       Impact factor: 3.451

8.  Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose.

Authors:  Jingchuan Guo; Wei-Hsuan Lo-Ciganic; Qingnan Yang; James L Huang; Jeremy C Weiss; Gerald Cochran; Daniel C Malone; Courtney C Kuza; Adam J Gordon; Julie M Donohue; Walid F Gellad
Journal:  J Gen Intern Med       Date:  2021-01-22       Impact factor: 5.128

9.  One year mortality of patients treated with naloxone for opioid overdose by emergency medical services.

Authors:  Scott G Weiner; Olesya Baker; Dana Bernson; Jeremiah D Schuur
Journal:  Subst Abus       Date:  2020-04-03       Impact factor: 3.716

10.  "This is part of emergency medicine now": A qualitative assessment of emergency clinicians' facilitators of and barriers to initiating buprenorphine.

Authors:  Elizabeth M Schoenfeld; William E Soares; Emily M Schaeffer; Jacob Gitlin; Kimberly Burke; Lauren M Westafer
Journal:  Acad Emerg Med       Date:  2021-09-07       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.